Distribution pattern of the Ki67 labelling index in breast cancer and its implications for choosing cut-off values

Breast

Volumn 23, Issue 3, 2014, Pages 259-263

  Cserni, Gábor ^a,b   Vörös, András ^b   Liepniece Karele, Inta ^c   Bianchi, Simonetta ^d   Vezzosi, Vania ^d   Grabau, Dorthe ^e   Sapino, Anna ^f   Castellano, Isabella ^f   Regitnig, Peter ^g   Foschini, Maria Pia ^h   Zolota, Vassiliki ⁱ   Varga, Zsuzsanna ^j   Figueiredo, Paulo ^k   Decker, Thomas ^l   Focke, Cornelia ^l   Kulka, Janina ^m   Kaya, Handan ⁿ   Reiner Concin, Angelika ^o   Amendoeira, Isabel ^p   Callagy, Grace ^q   Caffrey, Emer ^q   Wesseling, Jelle ^r   Wells, Clive ^s   more..

^a BÁCS KISKUN COUNTY TEACHING HOSPITAL   (Hungary)

^b UNIVERSITY OF SZEGED   (Hungary)

^c RIGA EAST UNIVERSITY HOSPITAL   (Latvia)

^d UNIVERSITY OF FLORENCE   (Italy)

^e LUND UNIVERSITY HOSPITAL   (Sweden)

^f UNIVERSITY OF TURIN   (Italy)

^g MEDICAL UNIVERSITY OF GRAZ   (Austria)

^h UNIVERSITY OF BOLOGNA   (Italy)

ⁱ UNIVERSITY OF PATRAS   (Greece)

^j UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^k Lab Histopatologia   (Portugal)

^l Dietrich Bonhoeffer Clinical Centre   (Germany)

^m SEMMELWEIS UNIVERSITY   (Hungary)

ⁿ MARMARA UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^o DANUBE HOSPITAL   (Austria)

^p Centro Hospitalar Universitário de São João   (Portugal)

^q NATIONAL UNIVERSITY OF IRELAND   (Ireland)

^r ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^s UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

more..

Author keywords

Breast cancer; Ki67; Proliferation

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; TUMOR MARKER;

ANTIBODY LABELING; ANTIGEN DETECTION; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER GRADING; CLINICAL PRACTICE; HUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; BREAST NEOPLASMS; CELL NUCLEUS; CLINICAL TRIAL; COMPARATIVE STUDY; FEMALE; IMMUNOHISTOCHEMISTRY; METABOLISM; MITOSIS INDEX; MULTICENTER STUDY; PATHOLOGY; PREDICTIVE VALUE; PROCEDURES; PROGNOSIS; REFERENCE VALUE; STAINING; STANDARDS;

BREAST NEOPLASMS; CELL NUCLEUS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MITOTIC INDEX; NEOPLASM GRADING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; REFERENCE VALUES; STAINING AND LABELING; TUMOR MARKERS, BIOLOGICAL;

EID: 84899907977     PISSN: 09609776     EISSN: 15323080     Source Type: Journal    
DOI: 10.1016/j.breast.2014.02.003     Document Type: Article

References (16)

1. Gerdes J., Li L., Schlueter C., Duchrow M., Wohlenberg C., Gerlach C., et al. Immunobiochemical and molecular biologic characterization of the cell proliferation-associated nuclear antigen that is defined by monoclonal antibody Ki-67. Am J Pathol 1991, 138:867-873.
2. Yerushalmi R., Woods R., Ravdin P.M., Hayes M.M., Gelmon K.A. Ki67 in breast cancer: prognostic and predictive potential. Lancet Oncol 2010, 11:174-183.
3. Aleskandarany M.A., Rakha E.A., Macmillan R.D., Powe D.G., Ellis I.O., Green A.R. MIB1/Ki-67 labelling index can classify grade 2 breast cancer into two clinically distinct subgroups. Breast Cancer Res Treat 2011, 127:591-599.
4. Jones R.L., Salter J., A'Hern R., Nerurkar A., Parton M., Reis-Filh J.S., et al. Relationship between oestrogen receptor status and proliferation in predicting response and long-term outcome to neoadjuvant chemotherapy for breast cancer. Breast Cancer Res Treat 2010, 119:315-323.
5. Dowsett M., Nielsen T.O., A'Hern R., Bartlett J., Coombes R.C., Cuzick J., et al. Assessment of Ki67 in breast cancer: recommendations from the international Ki67 in breast Cancer working group. JNatl Cancer Inst 2011, 103:1656-1664.
6. Vörös A., Csörgo E., Nyári T., Cserni G. An intra- and interobserver reproducibility analysis of the Ki-67 proliferation marker assessment on core biopsies of breast cancer patients and its potential clinical implications. Pathobiology 2013, 80:111-118.
7. Varga Z., Diebold J., Dommann-Scherrer C., Frick H., Kaup D., Noske A., et al. How reliable is Ki-67 immunohistochemistry in grade 2 breast carcinomas? A QA study of the Swiss Working Group of Breast- and Gynecopathologists. PLoS One 2012, 7:e37379.
8. Goldhirsch A., Ingle J.N., Gelber R.D., Coates A.S., Thürlimann B., Senn H.J., et al. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol 2009, 20:1319-1329.
9. Goldhirsch A., Wood W.C., Coates A.S., Gelber R.D., Thürlimann B., Senn H.J., et al. Strategies for subtypes - dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 2011, 22:1736-1747.
10. Jalava P., Kuopio T., Juntti-Patinen L., Kotkansalo T., Kronqvist P., Collan Y. Ki67 immunohistochemistry: a valuable marker in prognostication but with a risk of misclassification: proliferation subgroups formed based on Ki67 immunoreactivity and standardized mitotic index. Histopathology 2006, 48:674-682.
11. Cheang M.C.U., Chia S.K., Voduc D., Gao D., Leung S., Snider J., et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. JNatl Cancer Inst 2009, 101:736-750.
12. de Azambuja E., Cardoso F., de Castro G., Colozza M., Mano M.S., Durbecq V., et al. Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients. Br J Cancer 2007, 96:1504-1513.
13. Elston C.W., Ellis I.O. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991, 19:403-410.
14. Spyratos F., Ferrero-Poüs M., Trassasrd M., Hacene K., Phillips E., Tubiana-Hulin M., et al. Correlation between MIB-1 and other proliferation markers. Clinical implications of the MIB-1 cutoff value. Cancer 2002, 15:2151-2159.
15. Reyal F., Hajage D., Savignoni A., Feron J.G., Bollet M.A., Kirova Y., et al. Long-term prognostic performance of Ki67 rate in early stage, pT1-pT2, pN0, invasive breast carcinoma. PLoS One 2013, 8:e55901.
16. Goldhirsch A., Winer E.P., Coates A.S., Gelber R.D., Piccart-Gebhart M., Thürlimann B., et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol 2013, 24:2206-2223.